{
    "nct_id": "NCT05109494",
    "official_title": "Phase II Trial of Neoadjuvant Hypofractionated Radiotherapy Versus Conventionally Fractionated Radiotherapy for Soft Tissue Sarcomas",
    "inclusion_criteria": "* Biopsy proven soft tissue sarcoma of the extremity, trunk, or head and neck\n* No prior sarcoma-directed chemotherapy or radiotherapy\n* Age ≥ 18 years\n* Karnofsky performance status ≥ 60\n* Able to understand and sign an informed consent\n* Life expectancy of greater than 12 weeks\n* Hypofractionated or conventionally fractionated radiotherapy using Intensity Modulated Radiation Therapy (IMRT) are both deemed feasible and safe neoadjuvant treatments, at the treating physician's discretion\n* Operable disease and medically fit for surgery, based on the opinion of the consulting surgeon; surgery within 5-14 days of completion of radiation therapy (RT)\n* Adequate bone marrow function as defined by absolute neutrophil count > 500/mcL, hemoglobin > 8 g/dL, platelets > 50,000/mcL; adequate renal function as defined by creatinine clearance > 30 mL/min\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant\n* Unable to undergo imaging or positioning necessary for radiotherapy planning",
    "miscellaneous_criteria": ""
}